Antiretroviral therapy with heart

American Journal of Therapeutics

Volumn 16, Issue 6, 2009, Pages 579-584

  Randell, Paul ^a   Moyle, Graeme ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Antiretroviral therapy; Cardiovascular disease; HIV

Indexed keywords

ABACAVIR; AMPRENAVIR; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; FIBRIC ACID DERIVATIVE; FOSAMPRENAVIR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ANTIVIRAL THERAPY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; GLUCOSE METABOLISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; METABOLIC DISORDER; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; ENDOTHELIUM, VASCULAR; GLUCOSE; HIV INFECTIONS; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; RISK ASSESSMENT; RISK FACTORS;

EID: 74549200313     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e318192116f     Document Type: Review

References (59)

1. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362:22-29.
2. Friis-Møller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17:1179-1193.
3. The DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356: 1723-1735.
4. DeWit S, Sabin CA, Weber R, et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients. Diabetes Care. 2008;31:1224-1229.
5. D:A:D Study Group, Sabin C, Worm S, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008;371:1417-1426.
6. Sterne JAC, May M, Bucher HC, et al. HAART and the heart: changes in coronary risk factors and implications for coronary risk in men starting antiretroviral therapy. J Intern Med. 2007;261:255-267. (Pubitemid 46255947)
7. Riddler SA, Smit E, Cole SR, et al. Impact of HIV Infection and HAART on serum lipids in men. JAMA. 2003;289: 2978-2982.
8. Grunfeld C, Pang M, Doerrler W, et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1992;74:1045-1052.
9. Wohl D, Scherzer R, Heymsfield S, et al. The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men. J Acquir Immune Defic Syndr. 2008;48:44-52. (Pubitemid 351600858)
10. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-2296.
11. Kuller L, SMART Study group. Elevated levels of interleukin-6 and D-dimers are associated with an increased risk of death in patients with HIV. Presented at: 15th Conference on Retroviruses and Opportunistic Infections; 3-6 February 2008; Boston, MA. Abstract 139.
12. Borai A, Livingstone C, Ferns GAA. The biochemical assessment of insulin resistance. Ann Clin Biochem. 2007; 44:324-342.
13. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237:E214-E223.
14. Fleischman A, Johnsen S, Systrom DM, et al. Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults. Am J Physiol Endocrinol Metab. 2007;292: E1666-E1673.
15. Noor MA, Seneviratne T, Aweeka FT, et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS. 2002;16:F1-F8.
16. Lee GA, Lo JC, Aweeka F, et al. Single-dose lopinavirritonavir acutely inhibits insulin-mediated glucose disposal in healthy volunteers. Clin Infect Dis. 2006;43: 658-660.
17. Noor MA, Flint OP, Maa JF, et al. Effects of atazanavir/ ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS. 2006;20:1813-1821.
18. Noor MA, Parker RA, O'Mara E, et al. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS. 2004;18:2137-2144.
19. Lee GA, Rao M, Mulligan K, et al. Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers. AIDS. 2007;21:2183-2190.
20. Noor MA, Lo JC, Mulligan K, et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS. 2001; 15:11-18.
21. Lee GA, Seneviratne T, Noor MA, et al. The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS. 2004;18:641-649.
22. Blumer RME, vanVonderen MGA, Sutinen J, et al. Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting antiretroviral therapy. AIDS. 2008;22:227-236.
23. Jackson A, Patel N, Lo G, et al. Effects of atazanavir or saquinavir QD with ritonavir 100 mg and tenofovir/ emtricitabine as initial therapy for HIV-1 infection on peripheral glucose disposal; a randomized open-label study. Presented at:Conference on Retroviruses andOpportunistic Infections; 25-28 February 2007; Los Angeles, CA. Poster 818.
24. Randell P, Jackson A, Taylor J, et al. The effects of fosamprenavir or lopinavir with ritonavir, lamivudine and tenofovir, as initial treatment for HIV-1 infection, on insulin sensitivity. Presented at: 11th European AIDS Conference; 24-28 October 2007; Madrid, Spain. Poster LBP92/1.
25. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem. 2000;275(27):20251-20254.
26. Caron M, Auclair M, Vigouroux C, et al. The HIV protease inhibitor indinavir impairs sterol regulatory elementbinding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes. 2001;50:1378-1388.
27. Miserez AR, Muller PY, Spaniol V. Indinavir inhibits sterol-regulatory element-binding protein-1c-dependent lipoprotein lipase and fatty acid synthase gene activations. AIDS. 2002;16:1587-1594.
28. Jones SP, Waitt C, Sutton R, et al. Effect of atazanavir and ritonavir on the differentiation and adipokine secretion of human subcutaneous and omental preadipocytes. AIDS. 2008;22:1293-1298.
29. Kim JA, Wei Y, Sowers JR. Role of mitochondrial dysfunction in insulin resistance. Circ Res. 2008;102:401-414.
30. Moyle GJ, Nelson MR, Hawkins D, et al. The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT). Q J Med. 1993;86:155-163.
31. Fontas E, Leth Fv, Sabin CA, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis. 2004;189: 1056-1074.
32. Boffito M, Collot-Teixeira S, Lorenzo FD, et al. Plasma exposure of 100 mg once (OD) and twice daily (BID) decreases HDL and CD36 expression but only BID dosing increases triglycerides (TG): potential impact of RTV on cardiovascular disease (CVD). Presented at: 15th Conference on Retroviruses and Opportunistic Infections; 3-6 February 2008; Boston, MA. Abstract 930.
33. Arribas JR, Pozniak AL, Gallant JE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients. J Acquir Immune Defic Syndr. 2008;47:74-78.
34. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients. JAMA. 2004;292: 191-201.
35. Moyle GJ, Sabin CA, Cartledge J, et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS. 2006;20:2043-2050.
36. vanLeth F, Phanuphak P, Stroes E, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med. 2004;1:e19.
37. Podzamczer D, Ferrer E, Sanchez P, et al. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine. J Acquir Immune Defic Syndr. 2007;44:139-147.
38. Gatell J, Salmon-Ceron D, Lazzarin A, et al. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Clin Infect Dis. 2007;44:1484-1492.
39. Moyle G, Fisher M, the SWEET Study Group. A randomized comparison of continued zidovudine plus lamivudine BID (AZT/3TC) versus switching to tenofovir DF plus emtricitabine (FTC/TDF) each plus efavirenz (EFV) in stable HIV-infected persons: 48 Week Study - Results of a Planned 24 week analysis. Presented at: 4th International AIDS Society Conference on HIV Pathogenesis; 22-25 July 2007; Sydney, Australia. Poster WEPEB028.
40. Möbius U, Lubach-Ruitman M, Castro-Frenzel B, et al. Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia. J Acquir Immune Defic Syndr. 2005;39:174-180.
41. Colafigli M, Giambenedetto SD, Bracciale L, et al. Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen. HIV Med. 2008;9:172-179.
42. Soriano V, Garcia-Gasco P, Vispo E, et al. Efficacy and safety of replacing lopinavir with atazanavir in HIVinfected patients with undetectable plasma viraemia: final results of the SLOAT trial. J Antimicrob Chemother. 2008;61: 200-205.
43. Negredo E, Ribalta J, Paredes R, et al. Reversal of atherogenic lipoprotein profile in HIV-1-infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. AIDS. 2002;16:1383-1389.
44. National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults(Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106:3143-3421.
45. Grundy SM, Cleeman JI, Merz CNB, et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation. 2004;110:227-239.
46. Stein JH, Merwood MA, Bellehumeur JL, et al. Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors. Am Heart J. 2004;147:e18.
47. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV-seronegative volunteers: ACTG Study A5047. AIDS. 2002;16:569-577.
48. Gerber JG, Rosenkranz SL, Fichtenbaum CJ, et al. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin. J Acquir Immune Defic Syndr. 2005;39:307-312.
49. Luc de Saint Martin, Vandhuick O, Guillo P, et al. Premature atherosclerosis in HIV-positive patients and cumulated time of exposure to antiretroviral therapy (SHIVA study) Atherosclerosis. 2006;185:361-367.
50. Currier JS, Kendall MA, Zackin R, et al. Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure. AIDS. 2005;19:927-933.
51. Maggi P, Perilli F, Lillo A, et al. An ultrasound-based comparative study on carotid plaques in HIV-positive patients vs. atherosclerotic and arteritis patients: atherosclerotic or inflammatory lesions? Coron Artery Dis. 2007; 18:23-29.
52. Madden E, Lee G, Kotler DP, et al. Association of antiretroviral therapy with fibrinogen levels in HIVinfection. AIDS. 2008;22:707-715.
53. Thomas CM, Smart EJ. How HIV protease inhibitors promote atherosclerotic lesion formation. Curr Opin Lipidol. 2007;18:561-565.
54. Wang X, Chai H, Yao Q, et al. Molecular mechanisms of HIV protease inhibitor-induced endothelial dysfunction. J Acquir Immune Defic Syndr. 2007;44:493-499.
55. Law M, Friis-Møller N, El-Sadr W, et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med. 2006;7:218-230.
56. Friis-Møller N, Thiebaut R, Reiss P, et al. Predicting the risk of coronary heart disease in HIV-infected patients: the D:A:D risk equation. Presented at: Conference on Retroviruses and Opportunistic Infections; 25-28 February 2007; Boston, MA. Poster 808.
57. Schambelan M, Benson CA, Carr A, et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA Panel. J Acquir Immune Defic Syndr. 2002;31:257-275.
58. Lundgren J, Battegay M, Behrens G, et al. European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med. 2008; 9:72-81.
59. B Gazzard on behalf of the BHIVA Writing Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med. 2006;7:487-503.